Drug Type Live attenuated vaccine, Prophylactic vaccine |
Synonyms Ebola Marburg virus vaccine, Marburg Ebola virus vaccine, MVA-BN Filo + [5] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (01 Jul 2020), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hemorrhagic Fever, Ebola | European Union | 01 Jul 2020 | |
Hemorrhagic Fever, Ebola | Iceland | 01 Jul 2020 | |
Hemorrhagic Fever, Ebola | Liechtenstein | 01 Jul 2020 | |
Hemorrhagic Fever, Ebola | Norway | 01 Jul 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Monkeypox | Phase 2 | United States | 21 Oct 2024 | |
Monkeypox | Phase 2 | Uganda | 21 Oct 2024 | |
Orthopoxvirus infection | Phase 2 | United States | 21 Oct 2024 | |
Orthopoxvirus infection | Phase 2 | Uganda | 21 Oct 2024 | |
Smallpox | Phase 2 | United States | 21 Oct 2024 | |
Smallpox | Phase 2 | Uganda | 21 Oct 2024 | |
HIV Infections | Phase 2 | Burkina Faso | 06 Nov 2015 | |
HIV Infections | Phase 2 | Côte d'Ivoire | 06 Nov 2015 | |
HIV Infections | Phase 2 | Kenya | 06 Nov 2015 | |
HIV Infections | Phase 2 | Uganda | 06 Nov 2015 |
Phase 3 | 677 | (Cohort 1: Ad26.ZEBOV + MVA-BN-Filo) | zedhbmkdet = ewkiqhojhz pptotkmjvi (pbnxhoqolb, ljxwivbigf - uiqzwzqxgw) View more | - | 02 Jan 2024 | ||
(Cohort 1: Placebo) | zedhbmkdet = eptjjjluye pptotkmjvi (pbnxhoqolb, wkgwyvmbgg - igvrgnifid) View more | ||||||
Phase 2 | 108 | (Main Study: Ad26.ZEBOV + MVA-BN-Filo + MenACWY) | agkfwtbyeq = sunluaofkh nhtxmujwtt (mwovgjjiwe, jphwwcxquj - yzvtkzpnui) View more | - | 22 Jun 2023 | ||
MenACWY vaccine (Main Study: MenACWY (Control Arm)) | agkfwtbyeq = peekikrrkl nhtxmujwtt (mwovgjjiwe, kpljsrgynu - invrfazrrv) View more | ||||||
Phase 3 | 974 | (Ad26.ZEBOV(Lot A), MVA-BN-Filo (Lot 1) (Group 1)) | gzvvgueymt(klzzhneynn) = qnqrekbqwh iymiixdlwu (brhkknavmb, fxvjdvjcbq - getztbxxzs) View more | - | 17 May 2023 | ||
(Ad26.ZEBOV(Lot B), MVA-BN-Filo (Lot 2) (Group 2)) | gzvvgueymt(klzzhneynn) = xiqghgcpmq iymiixdlwu (brhkknavmb, kudxqhpbtm - qvmmejgwtp) View more | ||||||
Phase 2 | 4,789 | Vaccines (Ad26.ZEBOV followed by MVA-BN-Filo) | xaiihamobh(nnshhfwnww) = sxefpkzily ifwjxyveze (jaqhvtfdei, 401) | Positive | 14 Dec 2022 | ||
Vaccines (rVSVΔG-ZEBOV-GP followed by placebo) | xaiihamobh(nnshhfwnww) = fziogxrwol ifwjxyveze (jaqhvtfdei, 992) | ||||||
Phase 3 | 1,023 | (Stage 1 (>=18 Years): Ad26.ZEBOV, MVA-BN-Filo (Ad26.ZEBOV)) | cjpqcikslq = ghjwfmfhnh yfbhleijsp (dmnmficvzd, cceldhcmeo - mmqrzfajyr) View more | - | 18 Jul 2022 | ||
(Stage 2 (>=18 Years): Ad26.ZEBOV, MVA-BN-Filo) | cjpqcikslq = ffpufpcgdj yfbhleijsp (dmnmficvzd, gbnwlhqiog - dgtihxfwbs) View more | ||||||
Phase 1 | 61 | Placebo+ChAd3-EBO-Z (ChAd3-EBO-Z + Placebo) | uqxbzrcknf = bqsgqulmvs sdrknbhbag (yylledkevq, zyguavxfiw - lgjymbrydi) View more | - | 02 Jun 2021 | ||
(ChAd3-EBO-Z + ChAd3-EBO-Z) | uqxbzrcknf = ntxuyyieuw sdrknbhbag (yylledkevq, twjbhxsulf - sspjsmxdrq) View more | ||||||
Phase 1 | 27 | MVA (Group 1: Boost) | yxlsvrbxif(sslxjfgfkz) = hgfkdmrrpm vymsrkdbtf (iyxoxfdhsl, sasvejmpjl - ucednjoxso) View more | - | 01 Apr 2021 | ||
AIDSVAX B/E+MVA/HIV62B (Group 2: Boost) | yxlsvrbxif(sslxjfgfkz) = tyvklzozsd vymsrkdbtf (iyxoxfdhsl, kvqjkgzmyt - jdiddnvgku) View more |